[go: up one dir, main page]

WO2019106427A3 - Procédé de criblage d'agents d'inversion de latence du vih-1 - Google Patents

Procédé de criblage d'agents d'inversion de latence du vih-1 Download PDF

Info

Publication number
WO2019106427A3
WO2019106427A3 PCT/IB2018/001456 IB2018001456W WO2019106427A3 WO 2019106427 A3 WO2019106427 A3 WO 2019106427A3 IB 2018001456 W IB2018001456 W IB 2018001456W WO 2019106427 A3 WO2019106427 A3 WO 2019106427A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
latency reversing
reversing agents
fraction
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/001456
Other languages
English (en)
Other versions
WO2019106427A2 (fr
Inventor
Privada Institut De Recerca De La Sida-Caixa Fundacio
Julia GARCIA PRADO
Alba RUIZ DE ANDRES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IrsiCaixa Institut de Recerca de la Sida
Original Assignee
IrsiCaixa Institut de Recerca de la Sida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IrsiCaixa Institut de Recerca de la Sida filed Critical IrsiCaixa Institut de Recerca de la Sida
Publication of WO2019106427A2 publication Critical patent/WO2019106427A2/fr
Publication of WO2019106427A3 publication Critical patent/WO2019106427A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé avec des agents d'inversion de latence du VIH-1 (LRA). Le procédé comprend les étapes consistant à : (a) cultiver in vitro une fraction de lymphocytes T CD4+ obtenus à partir d'un sujet infecté par le VIH avec au moins un agent d'inversion de latence (LRA) pendant au moins 48 heures, (b) co-cultiver in vitro la fraction de lymphocytes T CD4+ avec des lymphocytes-T cytotoxiques (CTL) obtenus à partir du sujet infecté par le VIH et (c) compter les lymphocytes T CD4+ tués dans la fraction.
PCT/IB2018/001456 2017-11-22 2018-11-21 Procédé de criblage d'agents d'inversion de latence du vih-1 Ceased WO2019106427A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762590081P 2017-11-22 2017-11-22
US62/590,081 2017-11-22

Publications (2)

Publication Number Publication Date
WO2019106427A2 WO2019106427A2 (fr) 2019-06-06
WO2019106427A3 true WO2019106427A3 (fr) 2019-10-17

Family

ID=66379947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/001456 Ceased WO2019106427A2 (fr) 2017-11-22 2018-11-21 Procédé de criblage d'agents d'inversion de latence du vih-1

Country Status (1)

Country Link
WO (1) WO2019106427A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024210907A1 (fr) * 2023-04-07 2024-10-10 The Johns Hopkins University Anticorps bispécifiques tcr-mimtc pour vih-1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016063251A1 (fr) * 2014-10-23 2016-04-28 Centre Hospitalier Universitaire Vaudois Réactifs et procédés de réactivation du vih latent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016063251A1 (fr) * 2014-10-23 2016-04-28 Centre Hospitalier Universitaire Vaudois Réactifs et procédés de réactivation du vih latent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B. JONES ET AL: "Evaluating CTL-Based ''Flush and Kill'' HIV Eradication Strategies Against Primary Cell Models of Latency and Natural Viral Reservoirs", AIDS RESEARCH AND HUMAN RETROVIRUSES., vol. 29, no. 11, 1 November 2013 (2013-11-01), US, pages A - 183, XP055600560, ISSN: 0889-2229, DOI: 10.1089/aid.2013.1500 *
CHI N. CHAN ET AL: "HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells", RETROVIROLOGY, vol. 13, no. 1, 5 January 2016 (2016-01-05), XP055600436, DOI: 10.1186/s12977-015-0234-9 *
DATSEN GEORGE WEI ET AL: "Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing", PLOS PATHOGENS, vol. 10, no. 4, 10 April 2014 (2014-04-10), pages e1004071, XP055240697, DOI: 10.1371/journal.ppat.1004071 *
LIANG SHAN ET AL: "Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation", IMMUNITY, CELL PRESS, US, vol. 36, no. 3, 5 January 2012 (2012-01-05), pages 491 - 501, XP028475174, ISSN: 1074-7613, [retrieved on 20120227], DOI: 10.1016/J.IMMUNI.2012.01.014 *

Also Published As

Publication number Publication date
WO2019106427A2 (fr) 2019-06-06

Similar Documents

Publication Publication Date Title
WO2020172492A3 (fr) Préparations de membrane bactérienne
WO2021127159A3 (fr) Electrodes métalliques au lithium
AU2018271755A1 (en) Method for culturing natural killer cell, using transformed T cell
AU2020337417A8 (en) Organoid mesoderm lineage diversification
MX2022001257A (es) Composiciones y preparaciones de células nk para inmunoterapia y métodos para su producción.
EP4530350A3 (fr) Technologie de torchère améliorée (flow cytoméro attenued reporter expression) pour tri en vrac rapide
EP3750549A3 (fr) Composition pour induire la prolifération ou l'accumulation de lymphocytes t régulateurs
EP4006030A3 (fr) Procédés et compositions d'inhibition de l'interaction de ménine avec des protéines mll
MY161389A (en) Method for amplifying nk cells
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
IL246525B (en) Pomegranate cell culture and methods for its preparation and use
MX393763B (es) Nanosistemas que comprenden plata y antibioticos y su uso para el tratamiento de infecciones bacterianas
EP3746049A4 (fr) Vésicules extracellulaires issues de cellules cultivées dans des conditions hypoxiques et leurs utilisations
WO2021101273A3 (fr) Composition pour la culture de lymphocytes t régulateurs et son utilisation
WO2019224713A3 (fr) Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
WO2018213815A3 (fr) Lyse synthétique régulée par quorum
EP4545589A3 (fr) Compositions comprenant du glucose et de l'hémicellulose et leur utilisation
WO2020205626A8 (fr) Modulateurs d'interactions de protéine de surface cellulaire et procédés et compositions associés à ceux-ci
EP3999078A4 (fr) Procédés de culture de cellules souches mésenchymateuses, produits associés et leurs applications
EP4039796A4 (fr) Procédé de production de composition pour la culture cellulaire, composition pour la culture cellulaire obtenue par ce dernier, et procédé de culture cellulaire l'utilisant
EP2564929A3 (fr) Ensemble de cales de distance pour un concasseur à mâchoires
WO2020205969A8 (fr) Procédés pour améliorer la régénération de lymphocytes t
SG10201809259SA (en) Microbiological growth media and methods of using the same
WO2019106427A3 (fr) Procédé de criblage d'agents d'inversion de latence du vih-1
SG10201811177SA (en) Cell culture methods and media comprising n-acetylcysteine

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18874988

Country of ref document: EP

Kind code of ref document: A2